- GlycoMimetics (GLYC -4%) inks an agreement with Haemato Oncology Foundation for Adults in the Netherlands (NOVON), a cooperative clinical trial there, to initiate a clinical study evaluating GMI-1271, combined with the chemo agent decitabine, in adults with newly diagnosed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot tolerate intensive chemotherapy.
- Key efficacy measures in the 140-subject trial, expected to start later this year, will be remission rate, disease-free survival and overall survival.
- Separately, the company will announce the design of its planned Phase 3 study of GMI-1271 in relapsed/refractory AML during its Q4 earnings call on March 6.
- GMI-1271 is an E-selectin antagonist that disrupts known pathways of tumor resistance which improves the effectiveness of chemotherapy.
- Previously: GlycoMimetics' GMI-1271 shows positive effect in Phase 1/2 AML study; shares ahead 24% premarket (Dec. 12, 2017)
- Now read: Why GlycoMimetics Is Up Over 400% In Less Than A Year
Original article